Rightly so, the Q1 numbers showed revenue increasing over 80% pcp but the 1H numbers are up around 65% pcp. This means the growth in Q2FY22 vs Q2FY21 was was only around 40%. Ballpark numbers but that's what I think disappointment the market.
I am happy giving them the benefit of doubt. Compared to a lot of spec health stocks, PEB looks like they have a beneficial solution. As long as the product is actually going to save the healthcare system money, I'm sure it will eventually get adopted more broadly.
Ann: Half Yearly Report and Accounts, page-3
Add PEB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $97.42M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5000 | 12.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.0¢ | 4296 | 1 |
View Market Depth
| Last trade - 16.12pm 04/10/2024 (20 minute delay) ? |
| PEB (ASX) Chart |
Day chart unavailable